Hepatitis C Information - FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950

FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
PR Newswire - CAMBRIDGE, Mass., Dec. 8 /PRNewswire-FirstCall/ -- Vertex PharmaceuticalsIncorporated (Nasdaq: VRTX) today announced that the U.S. Track designation to VX-950for the following reasons: * Chronic hepatitis C virus infection is a serious and life

(PRN) - Three Rivers Pharmaceuticals Announces FDA Final Approval of Ribasphere(R) (ribavirin, USP) Tablets 60
Bolsamania - Three Rivers Pharmaceuticals Announces FDA Final Approval of Ribasphere(R) (ribavirin, USP) Tablets 600mg, 400mg and 200mg for the Treatment of Chronic Hepatitis C 05/12/2005 - 18:50 - (BMS) - PRNewswireCRANBERRY TOWNSHIP, Pa.Dec.

Novelos Therapeutics, Inc. Gets Green Light From FDA For Phase 3 Development In Lung Cancer
BioSpace - cancer and our second compound, NOV-205, targeting chronic hepatitis C.' ' We are pleased that the FDA has considered